Q3 EPS Forecast for Viking Therapeutics Boosted by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) – HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, July 30th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($1.12) for the quarter, up from their previous estimate of ($1.15). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($4.50) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($4.74) EPS and FY2027 earnings at ($6.04) EPS.

A number of other analysts have also recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Viking Therapeutics from $107.00 to $114.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Friday, July 17th. Morgan Stanley set a $95.00 target price on Viking Therapeutics in a research report on Thursday, April 30th. Zacks Research lowered Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 20th. Finally, Lake Street Capital assumed coverage on Viking Therapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $89.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Viking Therapeutics has an average rating of “Moderate Buy” and an average target price of $97.88.

Viking Therapeutics Stock Performance

Shares of VKTX stock opened at $32.61 on Monday. The firm has a fifty day moving average of $34.20 and a 200-day moving average of $32.99. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of -7.00 and a beta of 0.69. Viking Therapeutics has a 52-week low of $22.96 and a 52-week high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.11. During the same period last year, the business earned ($0.58) earnings per share. Viking Therapeutics’s quarterly revenue was up .0% on a year-over-year basis.

Insider Buying and Selling

In other news, CEO Brian Lian sold 148,517 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $33.32, for a total transaction of $4,948,586.44. Following the sale, the chief executive officer owned 2,572,441 shares in the company, valued at approximately $85,713,734.12. This represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Marianna Mancini sold 18,217 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $33.47, for a total value of $609,722.99. Following the completion of the sale, the chief operating officer owned 422,760 shares of the company’s stock, valued at approximately $14,149,777.20. This trade represents a 4.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 187,951 shares of company stock worth $6,268,442 in the last three months. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Viking Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raleigh Capital Management Inc. grew its stake in shares of Viking Therapeutics by 58.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 347 shares during the last quarter. Ballast Advisors LLC acquired a new position in Viking Therapeutics during the 1st quarter worth $33,000. Quattro Advisors LLC bought a new position in Viking Therapeutics in the 4th quarter valued at $37,000. Fifth Third Bancorp increased its stake in shares of Viking Therapeutics by 169.2% in the 4th quarter. Fifth Third Bancorp now owns 1,077 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 677 shares during the period. Finally, TD Waterhouse Canada Inc. raised its position in shares of Viking Therapeutics by 250.0% during the fourth quarter. TD Waterhouse Canada Inc. now owns 1,400 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.